Autoimmunity BioSolutions

Autoimmunity BioSolutions is a seed-stage biotechnology company developing next-generation immune-correcting antibody therapies for the treatment of autoimmune diseases to restore normal immune function. The therapy targets a subset of patients with genetically defined autoimmune diseases, characterized by a highly prevalent genetic variation (SNP), which is associated with an increased risk and severity of various autoimmune conditions. This immune-correction approach to treating autoimmune diseases differs significantly from current care standards that rely on immune-suppression mechanisms and holds broad potential for treating a wide range of autoimmune disorders.